Hugel Inc
KOSDAQ:145020
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
143 500
321 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hugel Inc
Total Liabilities & Equity
Hugel Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Liabilities & Equity
₩943B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Liabilities & Equity
₩19.9T
|
CAGR 3-Years
56%
|
CAGR 5-Years
40%
|
CAGR 10-Years
24%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Liabilities & Equity
₩1.9T
|
CAGR 3-Years
49%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Green Cross Corp
KRX:006280
|
Total Liabilities & Equity
₩2.8T
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Liabilities & Equity
₩601.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Liabilities & Equity
₩299.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Hugel Inc
Glance View
Hugel, Inc. engages in the manufacture and sale of biopharmaceuticals based on clostridium botulinum. The company is headquartered in Chuncheon, Gangwon-Do. The company went IPO on 2015-12-24. The firm's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The firm sells its products in domestic and overseas markets.
See Also
What is Hugel Inc's Total Liabilities & Equity?
Total Liabilities & Equity
943B
KRW
Based on the financial report for Sep 30, 2024, Hugel Inc's Total Liabilities & Equity amounts to 943B KRW.
What is Hugel Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
1%
Over the last year, the Total Liabilities & Equity growth was -5%. The average annual Total Liabilities & Equity growth rates for Hugel Inc have been -2% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
